<DOC>
	<DOCNO>NCT01164605</DOCNO>
	<brief_summary>The substitution raltegravir NRTIs result reversal long term adverse effect lipodystrophy ( specifically peripheral lipoatrophy ) associate chronic use NRTIs . Changing HAART regimen patient sustain virological response PI plus NRTI regimen PI plus raltegravir likely result continue virologic efficacy .</brief_summary>
	<brief_title>Pilot Study Raltegravir Lipodystrophy IISP</brief_title>
	<detailed_description>A prospective , non-controlled , non-randomized , single center study treatment regimen protease inhibitor non-nucleoside reverse transcriptase inhibitor combination raltegravir patient HIV-1 infection , continue , fully control standard HAART regimen PI NNRTI plus 2 NRTIs , effect change regimen peripheral fat distribution . This pilot study contain 30 patient follow period one year start date medication change NRTI-based regimen raltegravir-based NRTI-sparing regimen . Potential change fat distribution ( fat content assess fat volume ) measure serial MRI 's thigh .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . HIV1 positive 2 . Any patient boost PI plus 2 NRTIs . 3 . Visual evidence peripheral fat waste 4 . HIV1 viral load fully suppress least 9mths . 1 . Historical resistance PI patient receive 2 . No prior exposure raltegravir , elvitegravir , HIV1 integrase inhibitor . 3 . No contraindication serial MRI scanning . 4 . No contraindication utilization raltegravir . 5 . Not currently receive medication drugdrug interaction w/ raltegravir .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>NRTI-regimen</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Elvitegravir</keyword>
	<keyword>HIV-1 integrase inhibitor</keyword>
	<keyword>Fat Waste</keyword>
</DOC>